Tianeptine Results Timeline: What Studies Measured, and When

Questions about tianeptine timing — when changes appeared, what was measured at which week — are answered in the literature by looking at what investigators actually recorded and when they recorded it. That is a different question from what any individual would experience. This page walks through the measurement timepoints reported in the verified papers below, labels each as preclinical or clinical, and states plainly where human timepoint data is absent. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medication.

First, What Kind of Compound the Literature Describes

A chemical-neuroscience review of tianeptine traced its synthesis, pharmacology, and clinical history, and described its activity at the μ-opioid receptor alongside its long-standing use as an antidepressant in several countries, as well as reports of misuse and withdrawal associated with unapproved products (PMID 39382192). That framing matters for any timeline discussion: a compound with receptor-level activity may produce acute pharmacological signals on a timescale of minutes to hours, while any mood-related endpoints measured in psychiatry are conventionally assessed over weeks.

A historical analysis applying operational criteria to antidepressant discovery placed tianeptine among agents whose development pathways were examined for the role of serendipity, underlining that the compound emerged from an era when mechanism and clinical observation were often reconstructed after the fact (PMID 40352067). Because of that history, much of the mechanistic timeline evidence available today comes from animal models rather than from densely sampled human trials.

Acute Timepoints: Hours After a Single Administration (Preclinical)

Labelled: animal data. The shortest measurement windows in the verified set come from rodent pain work. Researchers reported that tianeptine produced antiallodynic effects in a mouse model of neuropathic pain, and the study characterised those effects as lasting rather than confined to the immediate post-dose interval (PMID 37474762). The relevant point for a timeline is structural: that work sampled behaviour both acutely after administration and again after the acute pharmacological window had passed, and reported persistence of the measured effect.

Receptor-level pharmacology sits on an even shorter clock. A neuropharmacology study of μ-receptor activation compared how different ligands engage the receptor and described a distinctive activation mechanism for the biased agonist SR-17018, work that was conducted in the same receptor space the tianeptine review identified as relevant to tianeptine's pharmacology (PMID 39067665, PMID 39382192). Receptor-binding and signalling assays report on the order of seconds to minutes in vitro; they do not translate into a behavioural or clinical timeline.

Sub-Chronic Timepoints: Days to Three Weeks (Preclinical)

Labelled: animal data. The most detailed timepoint information for tianeptine in the verified literature comes from rat social-isolation models, where dosing ran for weeks before tissue and behaviour were sampled.

One study examined synaptic vesicle dynamics and synaptic mitochondrial processes in socially isolated rats and reported that tianeptine modulated vesicle dynamics and favoured synaptic mitochondrial processes in that model (PMID 34493757). This is an endpoint-at-sacrifice design: the measurement is made once, at the end of the dosing and isolation period, so it tells readers what had changed by that point rather than when the change began.

A companion metabolomic investigation profiled hippocampal tissue and related tianeptine effectiveness to restoration of GABA, myo-inositol, cholesterol, and fatty acid metabolism in socially isolated rats (PMID 35776189). Again, the metabolomic snapshot was taken after the chronic stress-plus-treatment period, so the timeline claim supported is "detectable by the end of the protocol," not "detectable on day 3."

Longer-horizon animal work exists outside the brain as well. Researchers reported anti-osteoporotic effects of tianeptine in ovariectomized rats, a model in which bone endpoints require weeks of dosing before densitometric and histological differences can be measured (PMID 28081469). Bone outcomes are inherently slow-reading endpoints; that study's timeline is dictated by bone remodelling biology, not by how fast the drug reaches the brain.

What the Preclinical Timeline Does and Does Not Establish

• Single-session measurement. The synaptic and metabolomic rat studies reported endpoints at one terminal timepoint, so onset within the dosing period was not mapped (PMID 34493757, PMID 35776189).
• Persistence was specifically tested in one pain model. The neuropathic-pain study reported lasting antiallodynic effects, which is a persistence claim rather than an onset claim (PMID 37474762).
• Species and model gap. Socially isolated rats and ovariectomized rats are disease models, and none of these designs measured human symptom scales (PMID 35776189, PMID 28081469).

Clinical Timepoints: Where the Human Evidence Sits

Stated plainly: the verified source set here does not contain a tianeptine-specific human trial reporting week-by-week symptom scores. What it does contain are reviews and meta-analyses in which antidepressants as a class were assessed over defined windows, which is the level at which clinical timelines can honestly be discussed here.

A systematic review and network meta-analysis examined antidepressants for adults with major depressive disorder in the maintenance phase, which is by definition the period after acute response, when the research question shifts from "did symptoms improve" to "was improvement sustained over months" (PMID 36253442). Maintenance-phase analyses are the clearest illustration that antidepressant literature treats the long horizon — relapse over months — as a separate measurement question from the acute horizon.

On the acute side, a meta-review of antidepressants in children and adolescents evaluated efficacy, tolerability and suicidality specifically in acute treatment, which in that literature is the initial weeks-long window rather than the maintenance period (PMID 32982805). Together, these two reviews sketch the conventional two-stage clinical timeline — acute assessment first, maintenance assessment afterward — without attributing any specific tianeptine week-by-week figure to either (PMID 36253442, PMID 32982805).

Population-specific pharmacokinetics also shape timelines. A systematic review of antidepressants for depression in stage 3–5 chronic kidney disease assessed pharmacokinetics, efficacy and safety and issued recommendations through European Renal Best Practice (PMID 22859791). Reviews of that type exist because drug handling — and therefore the time course of exposure — differs between populations.

Timeline Table: What Was Measured, and When

Safety and Tolerability Over Time: What Studies Report

Timeline discussions cannot be separated from tolerability, because adverse events also have their own timepoints. The chemical-neuroscience review of tianeptine described reports of misuse and withdrawal connected to the compound's μ-opioid activity and to unapproved products, situating those concerns alongside its regulated antidepressant use in some jurisdictions (PMID 39382192). Dependence-related phenomena are, by their nature, phenomena of repeated exposure over time rather than of a single administration.

At the class level, the youth meta-review assessed tolerability and suicidality during acute antidepressant treatment, which is the window in which treatment-emergent events are conventionally captured (PMID 32982805). The renal review separately evaluated safety alongside pharmacokinetics in stage 3–5 chronic kidney disease, reflecting that exposure-related risk can differ where clearance is impaired (PMID 22859791). None of these papers provides a tianeptine-specific adverse-event timeline, and readers should not infer one.

Why Mechanistic Findings Do Not Set a Personal Clock

Mechanistic studies increasingly report mitochondrial and synaptic endpoints, and those endpoints can move before or after — or independently of — anything observable in behaviour. Beyond the tianeptine-specific rat work on synaptic mitochondria (PMID 34493757), separate neuroscience research on targeting a Cend1–Atp5f1b interaction reported rescue of mitochondrial dysfunction and amelioration of ischemic brain injury, illustrating how mitochondrial endpoints are pursued as therapeutic targets in their own right (PMID 41469760). Comparable measurement logic appears in unrelated fields: a practitioner review and meta-analysis of pharmacological treatment for ADHD symptoms in children and youth with autism spectrum disorder synthesised trial outcomes across studies with differing follow-up lengths, a recurring source of heterogeneity in any timeline synthesis (PMID 32845025).

Reading a Timeline Page Critically

1. Check whether onset was actually sampled. Terminal-endpoint rodent designs report status at the end, as in the socially isolated rat studies (PMID 35776189).
2. Separate acute from maintenance questions. Class-level reviews treat these as distinct designs with distinct outcomes (PMID 36253442).
3. Do not convert animal protocol length into a human schedule. The ovariectomized-rat bone work and mouse pain work used model-specific windows (PMID 28081469, PMID 37474762).
4. Keep misuse and withdrawal in the frame. The review addressed these explicitly (PMID 39382192).

In short, the honest summary is that preclinical tianeptine timelines are documented at chronic endpoints and, for pain, as persistence beyond the acute window (PMID 37474762, PMID 34493757), while human timeline detail in the verified set is class-level rather than compound-specific (PMID 36253442).

References

• Classics in Chemical Neuroscience: Tianeptine (ACS Chemical Neuroscience, 2024)
• Tianeptine modulates synaptic vesicle dynamics and favors synaptic mitochondria processes in socially isolated rats (Scientific Reports, 2021)
• Metabolomic profiling relates tianeptine effectiveness with hippocampal GABA, myo-inositol, cholesterol, and fatty acid metabolism restoration in socially isolated rats (Psychopharmacology, 2022)
• Tianeptine promotes lasting antiallodynic effects in a mouse model of neuropathic pain (Neuropsychopharmacology, 2023)
• Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats (Biomedicine & Pharmacotherapy, 2017)
• Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis (Molecular Psychiatry, 2023)
• Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment (Frontiers in Psychiatry, 2020)
• Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP) (Nephrology, Dialysis, Transplantation, 2012)
• Activation of μ receptors by SR-17018 through a distinctive mechanism (Neuropharmacology, 2024)
• Did Serendipity Contribute to the Discovery of New Antidepressant Drugs? Historical Analysis Using Operational Criteria (Alpha Psychiatry, 2025)
• Targeting Cend1-Atp5f1b interaction rescues mitochondrial dysfunction and ameliorates ischemic brain injury (Communications Biology, 2025)
• Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis (Journal of Child Psychology and Psychiatry, 2021)